INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
Provided By PR Newswire
Last update: Mar 11, 2025
NEW YORK, March 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read more at prnewswire.com25.9
+1.25 (+5.07%)
Find more stocks in the Stock Screener
PCRX Latest News and Analysis
7 days ago - ChartmillPACIRA BIOSCIENCES INC (NASDAQ:PCRX), a growth stock which is not overvalued.Discover PACIRA BIOSCIENCES INC, an undervalued growth gem. NASDAQ:PCRX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
15 days ago - ChartmillWondering what's happening in today's after-hours session?The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
17 days ago - ChartmillPACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals.PACIRA BIOSCIENCES INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:PCRX showcases decent financial health and profitability, coupled with an attractive price.
